Yesterday, Amgen announced that it had submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand its license for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. If approved, XGEVA would be the first therapy licensed to prevent or [...]
According to findings from a long term study, men with prostate cancer (PCa) who are treated with degarelix (a newly approved gonadotropin-releasing hormone receptor (GnRH) blocker) have a lower risk of PSA failure or death compared with those treated with leuprolide. […]
Data from the recent ASCO conference on a phase II study of cabozantinib (XL184) in patients with advanced solid tumors, including prostate cancer, demonstrates that the investigational treatment has activity in both bone and soft tissue. This study evaluated the efficacy and safety of cabozantinib compared to placebo in 9 different solid tumor types including [...]
There is good reason for guarded optimism among men with advanced prostate cancer. Over the last 2 years we have seen some significant movement with the development of new drugs and treatments for men with advanced prostate cancer. All of these drugs have demonstrated a survival advantage in their clinical trials. Each of the agents [...]
In anticipation of our Monday night teleconference on Provenge (see below for registration procedures) I am very happy to report that Dendreon is now detailing plans to move Provenge to earlier stages in the disease’s progress. At the American Society of Clinical Oncology (ASCO) meeting in Chicago which is winding down today, Dendreon unveiled plans [...]
Today’s big news is about a media release made yesterday by Centocor Ortho Biotech with the official and final results of the Phase III clinical trial of abiraterone acetate (Zytiga™) plus prednisone vs. prednisone alone in men with metastatic, castration-resistant prostate cancer (mCRPC) who have already received at least one course of a docetaxel based [...]
Recent data presented at the 2011 Genitourinary Cancers Symposium supports the growing consensus that intermittent androgen suppression (IADT) is no less effective than continuous androgen suppression at treating men with prostate cancer that recurs after radiotherapy. Lead investigator, Laurence Klotz, MD, chief of urology, Sunnybrook Health Sciences Center, and professor of surgery at the University [...]
For our European readers who have not yet started, but are getting ready to start hormone deprivation therapy (ADT), there is a new clinical trial you should consider. This trial is evaluating MDV3100 monotherapy as the first hormonal treatment of patients with prostate cancer. Enrolled men would not have had any previous hormonal therapies for [...]
The long awaited FDA approval of Zytiga (abiraterone acetate), a once-daily oral agent, for the treatment of castration-resistant, metastatic prostate cancer following docetaxel chemotherapy has happened! Malecare celebrates this approval as it celebrates the significant numbers of new drug approvals we have had over the last year and one half. The approval of Zytiga represents [...]
Results from a recent international randomized phase II trial for the drug tasquinimod (TASQ), shows that TASQ is a potential therapy for men with advanced prostate cancer. The men who received TASQ on average went twice as long without disease progression as those who received only a placebo. […]
